TL;DR
Get business pricing on office and shipping supplies
- Business-only prices and quantity discounts
- Tax-exempt purchasing
- Multiple users, one account, clear invoices
Judges Scientific shares have lost nearly two-thirds of their value since reaching an all-time high in 2024, after a long period in which they significantly outperformed the FTSE All-Share. MoneyWeek argues the company’s difficulties appear more cyclical than structural, but the supplied report does not include current financial results or evidence that a recovery is underway.
Judges Scientific shares have fallen nearly two-thirds since reaching an all-time high in 2024, prompting MoneyWeek to argue that investors should consider buying the company again. The publication says the pressures appear more cyclical than structural, but that is an investment interpretation, not confirmation that the shares have bottomed or that a recovery has begun.
Judges Scientific, listed on AIM under the ticker JDG, was once a favourite among London-listed investors, according to MoneyWeek. The article reports that from March 2004 to March 2024, the shares rose 10,300%. Over the same period, the FTSE All-Share, excluding dividends, returned 160. Those figures describe past performance and do not establish how the shares will perform in future.
The company’s steep subsequent decline has changed how investors value it. MoneyWeek says the shares have shed nearly two-thirds since their 2024 high and notes that the group previously traded at more than 40 times forward earnings. It attributes the loss of investor patience to the fall, while suggesting the earlier valuation and market expectations may have made the shares vulnerable to disappointment.
The report’s central case is that Judges Scientific’s problems may reflect a downturn in trading conditions rather than a breakdown in the company’s business model. MoneyWeek describes the underlying model as intact and the challenges as apparently cyclical. The source material does not specify which trading indicators support that view, provide recent earnings figures, or set out a forecast for when conditions might improve.
A Sharp Repricing Raises the Stakes
The share-price drop matters because it has reversed a long period of exceptional historical gains and dramatically reduced the market’s valuation of the company. For existing shareholders, the decline represents a substantial loss from the 2024 peak. For potential buyers, the question is whether the lower price reflects temporary weakness or a lasting reduction in the company’s earning power.
MoneyWeek’s argument turns on that distinction. If the challenges are temporary, a lower valuation could make the shares more attractive than when they traded at over 40 times forward earnings. If business performance has weakened for lasting reasons, however, a large fall from the high would not by itself make the shares cheap. The supplied article extract does not provide enough financial detail to settle that question.
The story is also a reminder that past outperformance is not a guarantee of future returns. The 2004–24 comparison shows how dramatically the shares once outpaced the stated index measure; it does not demonstrate that investors who buy after the decline will see a similar result.
As an affiliate, we earn on qualifying purchases.
From Long-Term Winner to Steep Decline
MoneyWeek measures Judges Scientific’s earlier share-price rise over the 20 years from March 2004 to March 2024. Its comparison is with the FTSE All-Share excluding dividends, so it is not a total-return comparison that includes dividend income for the index. The report gives the share increase as 10,300% and the index return as 160% over that period.
The article then contrasts that record with the decline from the company’s all-time high in 2024. It says the shares have lost nearly two-thirds of their value and that the company once carried a forward-earnings valuation above 40 times. The supplied material does not identify the exact date of the peak, the share price at the time of writing, or the valuation after the decline.
MoneyWeek frames the sell-off as a potential opportunity rather than reporting a new company announcement, results release, or change in management. Its “time to buy” wording is an opinion based on the view that current difficulties are cyclical. Readers should distinguish that assessment from confirmed information about the company’s recent trading.
““the issues seem to be more cyclical than structural””
— MoneyWeek
As an affiliate, we earn on qualifying purchases.
Evidence Behind the Recovery Case
The source material does not detail the factors behind Judges Scientific’s recent difficulties, quantify their effect on revenue or earnings, or identify when trading might improve. It also does not give current results, cash-flow figures, debt information, management guidance, or a post-decline valuation. Those omissions mean the claim that the problems are cyclical cannot be independently tested using the supplied information.
It is also unclear whether the shares have reached a floor. A near-two-thirds fall from a peak describes the scale of the decline, not the company’s current value relative to its earnings or prospects. No recovery in the share price, change in investor sentiment, or specific catalyst is confirmed in the report.
The comparison with the FTSE All-Share covers a defined historical period and excludes dividends from the index return. It should not be treated as a forecast or as proof that the company will repeat its past performance.
As an affiliate, we earn on qualifying purchases.
Company Updates Will Test the Thesis
The next evidence for investors will need to come from Judges Scientific’s company disclosures, including financial results and any trading updates that explain current conditions and management’s expectations. Those updates could help show whether the weakness is easing, continuing, or affecting the business more persistently.
Until such information is available, MoneyWeek’s buy case remains an interpretation of the decline rather than a confirmed recovery signal. Investors assessing it would need to compare new operating and financial information with the company’s earlier performance and consider the risks as well as the lower share price. The supplied source does not state a date for a forthcoming results announcement or identify a specific next milestone.
As an affiliate, we earn on qualifying purchases.
Key Questions
What happened to Judges Scientific shares?
MoneyWeek reports that the shares have fallen nearly two-thirds since reaching an all-time high in 2024. The source does not give the exact peak date or the share price at the time of its report.
Why does MoneyWeek say the shares may be worth buying?
MoneyWeek argues that the company’s problems appear more cyclical than structural and that its underlying business model remains intact. This is the publication’s analysis; the supplied material does not include enough recent financial data to verify a recovery.
How did the shares perform before the decline?
The report says Judges Scientific shares rose 10,300% between March 2004 and March 2024. It compares that with a 160% return for the FTSE All-Share excluding dividends over the same period. These are historical figures, not forecasts.
No. A large decline from a previous high does not by itself show that a share is undervalued. The source material does not provide current earnings, a post-decline valuation, or enough detail to assess the company’s present financial position.
What remains unknown about the recovery case?
The supplied report does not specify the causes or financial impact of the recent weakness, when conditions might improve, or whether the shares have bottomed. Investors will need to assess future company disclosures to test MoneyWeek’s cyclical-downturn argument.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
